Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(895.58% Upside)
| Highest Price Target$60.00 | Average Price Target$45.00 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$60
Buy
1227.43%
Upside
Reiterated
12/12/25
JonesTrading
$30
Buy
563.72%
Upside
Reiterated
12/08/25
Precision BioSciences: Promising Advancements in Genetic Medicine with Key Data Updates Anticipated by 2026We see two key value inflection points in 2026 — (1) maturing cHBV data in 1Q26, and (2) initial data in DMD in 2026 (IND by YE25). Despite a crowded DMD space, drugs addressing individual exon mutations are being assigned significant implied valuations. Precision Bio's approach is highly differentiated. The drug is in vivo editing the dystrophin gene to express a functional truncated dystrophin protein, hence circumventing the need for developing separate drugs for different exon mutations. We see the present as being a good time to get into DTIL ahead of 2026 readouts. At AASLD on November 10th, Precision presented updated data from 9 patients from the Phase 1 ELIMINATE-B trial with PBGENE-HBV across three dose levels, including—(Cohort 1) 0.2 mg/kg, (Cohort 2) 0.4 mg/kg and (Cohort 3) 0.8 mg/kg (press release, presentation).
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$60
Buy
1227.43%
Upside
Reiterated
12/12/25
JonesTrading
$30
Buy
563.72%
Upside
Reiterated
12/08/25
Precision BioSciences: Promising Advancements in Genetic Medicine with Key Data Updates Anticipated by 2026We see two key value inflection points in 2026 — (1) maturing cHBV data in 1Q26, and (2) initial data in DMD in 2026 (IND by YE25). Despite a crowded DMD space, drugs addressing individual exon mutations are being assigned significant implied valuations. Precision Bio's approach is highly differentiated. The drug is in vivo editing the dystrophin gene to express a functional truncated dystrophin protein, hence circumventing the need for developing separate drugs for different exon mutations. We see the present as being a good time to get into DTIL ahead of 2026 readouts. At AASLD on November 10th, Precision presented updated data from 9 patients from the Phase 1 ELIMINATE-B trial with PBGENE-HBV across three dose levels, including—(Cohort 1) 0.2 mg/kg, (Cohort 2) 0.4 mg/kg and (Cohort 3) 0.8 mg/kg (press release, presentation).
Best Analysts Covering Precision BioSciences
1 Month
xxx
Success Rate
7/25 ratings generated profit
Average Return
-10.26%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 28.00% of your transactions generating a profit, with an average return of -10.26% per trade.
3 Months
xxx
Success Rate
2/22 ratings generated profit
Average Return
-18.14%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 9.09% of your transactions generating a profit, with an average return of -18.14% per trade.
1 Year
Success Rate
1/22 ratings generated profit
Average Return
-32.19%
reiterated a buy rating 8 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 4.55% of your transactions generating a profit, with an average return of -32.19% per trade.
2 Years
xxx
Success Rate
1/22 ratings generated profit
Average Return
-40.66%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 4.55% of your transactions generating a profit, with an average return of -40.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DTIL Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
5
10
11
12
Buy
0
0
0
0
0
Hold
15
12
11
7
5
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
21
17
21
19
18
Each month's total comprises the sum of three months' worth of ratings.
DTIL Financial Forecast
DTIL Stock Forecast FAQ
What is DTIL’s average 12-month price target, according to analysts?
Based on analyst ratings, Precision BioSciences’s 12-month average price target is 45.00.
What is DTIL’s upside potential, based on the analysts’ average price target?
Precision BioSciences has 895.58% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DTIL a Buy, Sell or Hold?
Precision BioSciences has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Precision BioSciences’s price target?
The average price target for Precision BioSciences is 45.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $30.00. The average price target represents 895.58% Increase from the current price of $4.52.
The highest analyst price target is $60.00 ,the lowest forecast is $30.00. The average price target represents 895.58% Increase from the current price of $4.52.
What do analysts say about Precision BioSciences?
Precision BioSciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of DTIL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.